Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies
纤维化发病机制和解决:从机制到治疗
基本信息
- 批准号:10678808
- 负责人:
- 金额:$ 0.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-15 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAccelerationAddressAgingAlberta provinceAreaAutomobile DrivingBiological MarkersBiological ProcessBiotechnologyCanadaCareer MobilityCessation of lifeChronicCicatrixClinicalClinical TrialsCollaborationsDevelopmentDiagnosisDiseaseEducationEducational workshopEpigenetic ProcessEventFibroblastsFibrosisFosteringGrowthHealth Care CostsHealthcare SystemsHeterogeneityHumanIndustryInfectious AgentInjuryInstitutionJointsKnowledgeLearningLinkLiver FibrosisMetabolicMethodologyMolecularNatural regenerationOncogenicOrganOrgan failureOutcomeParticipantPathogenesisPharmaceutical PreparationsPharmacologic SubstancePhysiciansPopulationResearchResearch PersonnelResolutionSafetyScientistSpeedSymptomsTechnologyTherapeuticTissuesTranslatingTranslationsTraumaVirus DiseasesWorkantifibrotic treatmentbench to bedsidecareerclinical practicecostdesigndrug discoveryhealingimprovedmultidisciplinarynext generationnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel strategiespostersresponsesymposiumtissue repair
项目摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Fibrosis Pathogenesis and Resolution:
From Mechanisms to Therapies, organized by Drs. David Lagares, Boris Hinz and Carine Boustany. The
conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023.
Human fibrotic diseases are characterized by progressive tissue scarring in response to overwhelming or
chronic injury, ultimately leading to organ failure and death. Fibrotic diseases cause healthcare costs reaching
$10 billion per year. These costs are expected to further increase with our aging populations, our increasing
capacity to diagnose fibrotic disorders and the emergence of novel infectious agents such as SARS-CoV-2,
which can promote the development of fibrosis. Therefore, this conference was designed to identify common
and distinct mechanisms driving fibrosis in response to different insults (e.g., viral infection, trauma, oncogenic
injury). This conference will also address the following emerging themes in the field: 1) the mechanisms which
amplify and perpetuate tissue fibrosis, such as aging, epigenetics, and mechanobiology, 2) the relevance of
fibroblast heterogeneity in tissue repair and fibrosis, and 3) understanding the mechanisms promoting fibrosis
resolution and regeneration to devise novel strategies to truly regenerate fibrotic organs. This forum will also
focus on major clinical challenges including the lack of robust fibrosis biomarkers, safety endpoints, and clinical
trial endpoints. Advances in these areas will break down barriers in translating anti-fibrotic therapies from
bench to bedside. This Keystone Symposia conference will accelerate fibrosis research and anti-fibrotic drug
discovery by fostering interdisciplinary interactions among a diverse group of physicians and scientists from
both academic institutions and the pharmaceutical and biotech industry. Finally, this conference will be held
jointly with Metabolic and Molecular Mechanisms of NAFLD/NASH. The joint conference will highlight current
evidence linking key biological processes involved in NASH and liver fibrosis. Participants from both
conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster
sessions.
抽象的
请求支持题为纤维化发病机制和解决方案的 Keystone 研讨会:
从机制到疗法,由 Drs 组织。大卫·拉加雷斯、鲍里斯·欣茨和卡琳·布斯塔尼。这
会议将于2023年3月19日至23日在加拿大艾伯塔省班夫举行。
人类纤维化疾病的特点是进行性组织疤痕响应压倒性或
慢性损伤,最终导致器官衰竭和死亡。纤维化疾病导致医疗费用达到
每年 100 亿美元。随着人口老龄化、人口老龄化和人口老龄化,这些成本预计将进一步增加。
诊断纤维化疾病和新型传染源(例如 SARS-CoV-2)的出现的能力,
从而可以促进纤维化的发展。因此,本次会议旨在确定共同点
以及响应不同损伤(例如病毒感染、创伤、致癌性)而驱动纤维化的不同机制
受伤)。本次会议还将讨论该领域的以下新兴主题:1)
放大和延续组织纤维化,例如衰老、表观遗传学和机械生物学,2)
组织修复和纤维化中成纤维细胞的异质性,3) 了解促进纤维化的机制
分辨率和再生来设计真正再生纤维化器官的新策略。本次论坛还将
专注于主要的临床挑战,包括缺乏强大的纤维化生物标志物、安全终点和临床
试验终点。这些领域的进展将打破将抗纤维化疗法转化为药物的障碍。
长凳到床边。本次Keystone Symposia会议将加速纤维化研究和抗纤维化药物
通过促进不同群体的医生和科学家之间的跨学科互动来发现
学术机构以及制药和生物技术行业。最后,这次会议将召开
与 NAFLD/NASH 的代谢和分子机制相结合。联席会议将重点关注当前
将 NASH 和肝纤维化相关的关键生物过程联系起来的证据。双方参与者
会议将有机会通过共享会议、用餐时间和晚间海报进行交流
会议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY L. SHEPPARD其他文献
TERRY L. SHEPPARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY L. SHEPPARD', 18)}}的其他基金
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Pulmonary Hypertension: State of the Art and Therapeutic Opportunities
肺动脉高压:最新技术和治疗机会
- 批准号:
10682118 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
B Cells and Tertiary Lymphoid Structures: Emerging Targets in Cancer Therapeutics
B 细胞和三级淋巴结构:癌症治疗的新兴靶点
- 批准号:
10754008 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Long COVID and Post Acute Sequalae of SARS CoV 2 (PASC): Pathogenesis and Treatment
长期新冠肺炎和 SARS CoV 2 (PASC) 急性后遗症:发病机制和治疗
- 批准号:
10749522 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Myeloid Cell Diversity: From Fundamental Biology to Disease States
骨髓细胞多样性:从基础生物学到疾病状态
- 批准号:
10753412 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy
处于癌症免疫治疗前沿的新兴细胞疗法
- 批准号:
10540496 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Infections in Pregnancy: PathogenicMechanisms, Experimental Advances and Clinical Strategies
妊娠期感染:致病机制、实验进展和临床策略
- 批准号:
10540260 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
相似国自然基金
基于增广拉格朗日函数的加速分裂算法及其应用研究
- 批准号:12371300
- 批准年份:2023
- 资助金额:43.5 万元
- 项目类别:面上项目
肠菌源性丁酸上调IL-22促进肠干细胞增殖加速放射性肠损伤修复的机制研究
- 批准号:82304065
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于肌红蛋白构象及其氧化还原体系探究tt-DDE加速生鲜牛肉肉色劣变的分子机制
- 批准号:32372384
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于联邦学习自动超参调整的数据流通赋能加速研究
- 批准号:62302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
M2 TAMs分泌的OGT通过促进糖酵解过程加速肝细胞癌恶性生物学行为的机制研究
- 批准号:82360529
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Neuroprotective Potential of Vaccination Against SARS-CoV-2 in Nonhuman Primates
SARS-CoV-2 疫苗对非人灵长类动物的神经保护潜力
- 批准号:
10646617 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory
密苏里大学区域生物防护实验室 NIH/NIAID 高优先级病原体研究的资源和劳动力发展
- 批准号:
10793827 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease
优化用于预防和治疗 HSV 疾病的单克隆抗体的生成
- 批准号:
10717320 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure
多维抗体工程可增强β冠状病毒医学对策的效力和广度
- 批准号:
10699866 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别: